August 6, 2024 04:01 PM EDTUpdated 07:18 PM
Pharma

Up­dat­ed: Am­gen's Hori­zon buy­out pow­ers growth, with Mar­i­Tide plans in­tact

Max Bayer

Pharma Reporter

Am­gen’s Hori­zon deal is start­ing to pay off, as the biotech gi­ant re­port­ed a 20% in­crease in quar­ter­ly rev­enue com­pared with the year pri­or. …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

TRENDING NOW

The End­points 11 win­ners: Big bets on AI, new fron­tiers in edit­ing, a neu­ro re­nais­sance and Chi­nese chem­istry

Ex­clu­sive: J&J folds car­dio­vas­cu­lar and meta­bol­ic drug unit

No­vo Nordisk to de­crease some in­sulin pen man­u­fac­tur­ing, tran­si­tion sup­ply

No­vo Nordisk CEO skep­ti­cal of PBM promis­es in Sen­ate hear­ing on weight loss drug prices

Cas­sa­va and its for­mer ex­ecs set­tle SEC charges for ‘mis­lead­ing’ Alzheimer’s drug da­ta

sponsored

PD­Cs vs. AD­Cs: A New Fron­tier in Tar­get­ed Can­cer Ther­a­pies and the Po­ten­tial for De­vel­op­ment Part­ner­ships

A service from the Financial Times